References
- Shor B, Gerber HP, Sapra P. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2):107–116.
- Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukaemia. N Engl J Med. 2016;375(8):740–753.
- Nice.org.uk. [Internet]. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Guidance and guidelines. NICE. 2019 [cited 2019 Sep 24]. Available from: https://www.nice.org.uk/guidance/TA541/chapter/1-Recommendations
- Reference costs 2017/18: highlights, analysis and introduction to the data [Internet]. 2018 [cited 2019 Sep 24]. Available from: https://improvement.nhs.uk/documents/1972/1_-_Reference_costs_201718.pdf
- NHSBT Pricing Proposals for 2017–18 [Internet]. 2016 [cited 2019 Sep 24]. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/2188/16-80.pdf.
- British National Formulary [Internet]. [cited 2019 Sep 24]. Available from: https://bnf.nice.org.uk/
- EMC Summary of Product Characteristics [Internet]. [cited 2019 Sep 24]. Available from: https://www.medicines.org.uk/emc/